Interferon-β and neuroprotection in multiple sclerosis-Facts, hopes and phantasies

Experimental Neurology

Volumn 203, Issue 1, 2007, Pages 1-4

  Kieseier, Bernd C ^a   Hartung, Hans Peter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB;

ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN ATROPHY; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; RETINA GANGLION CELL; SURVIVAL RATE; SURVIVAL TIME;

EID: 33751540077     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2006.09.007     Document Type: Note

References (50)

1. Anonymous. European Study Group on interferon beta-1b in secondary progressive multiple sclerosis. Placebo-controlled multicenter randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352 (1998) 1491-1497
2. Archelos J.J., and Hartung H.-P. Pathogenetic roles of autoantibodies in neurological diseases. Trends Neurosci. 23 (2000) 317-327
3. Archelos J.J., Storch M.K., and Hartung H.-P. The role of B cells and autoantibodies in multiple sclerosis. Ann. Neurol. 47 (2000) 694-706
4. Babbe H., Roers A., Waisman A., Lassmann H., Goebels N., Hohlfeld R., et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 192 (2000) 393-404
5. Benoist C., and Mathis D. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry?. Nat. Immunol. 2 (2001) 797-801
6. Biernacki K., Antel J.P., Blain M., Narayanan S., Arnold D.L., and Prat A. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch. Neurol. 62 (2005) 119-124
7. Bruck W., and Stadelmann C. The spectrum of multiple sclerosis: new lessons from pathology. Curr. Opin. Neurol. 18 (2005) 221-224
8. Cepok S., Rosche B., Grummel V., Vogel F., Zhou D., Sayn J., et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 128 (2005) 1667-1676
9. Cohen J.A., Cutter G.R., Fischer J.S., Goodman A.D., Heidenreich F.R., Kooijmans M.F., et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 59 (2002) 679-687
10. Coles A.J., Cox A., Le Page E., Jones J., Trip S.A., Deans J., et al. The window of therapeutic opportunity in multiple sclerosis. J. Neurol. 253 (2006) 98-108
11. Comi G., Filippi M., Barkhof F., Durelli L., Edan G., Fernandez O., et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357 (2001) 1576-1582
12. Compston A., and Coles A. Multiple sclerosis. Lancet 359 (2002) 1221-1231
13. Gold R., Linington C., and Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129 (2006) 1953-1971
14. Hemmer B., Archelos J.J., and Hartung H.P. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci. 3 (2002) 201-291
15. Hemmer B., Nessler S., Zhou D., Kieseier B.C., and Hartung H.P. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat. Clin. Pract. Neurol. 2 (2006) 201-211
16. Hertz F., and Deghenghi R. Effect of rat and beta-human interferons on hyperacute experimental allergic encephalomyelitis in rats. Agents Actions 16 (1985) 397-403
17. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 120 (1997) 865-916
18. Hohlfeld R., and Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) S14599-S14606
19. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Slazar A.M., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39 (1996) 285-294
20. Jacobs L.D., Beck R.W., Simon J.H., Kinkel R.P., Brownscheidle C.M., Murray T.J., et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. 343 (2000) 898-904
21. Kappos L., Polman C.H., Freedman M.S., Edan G., Hartung H.P., Miller D.H., et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67 (2006) 1242-1249
22. Kappos L., Weinshenker B., Pozzilli C., Thompson A.J., Dahlke F., Beckmann K., et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 63 (2004) 1779-1787
23. Kieseier B.C., and Hartung H.P. Current disease-modifying therapies in multiple sclerosis. Semin. Neurol. 23 (2003) 133-146
24. Kieseier B.C., and Hartung H.P. Multiple paradigm shifts in multiple sclerosis. Curr. Opin. Neurol. 16 (2003) 247-252
25. Kutzelnigg A., Lucchinetti C.F., Stadelmann C., Brück W., Rauschka H., Bergmann M., Schmidbauer M., Parisi J.E., and Lassmann H. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128 (2005) 2705-2712
26. Lang H.L., Jacobsen H., Ikemizu S., Andersson C., Harlos K., Madsen L., et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat. Immunol. 3 (2002) 940-943
27. Lassmann H. Multiple sclerosis pathology: evolution of pathogenetic concepts. Brain Pathol. 15 (2005) 217-222
28. Lassmann H., Bruck W., and Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol. Med. 7 (2001) 115-121
29. Lucchinetti C., Brück W., Parisi J., Scheithauer B., Rodriguez M., and Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47 (2000) 707-717
30. Maier K., Kuhnert A.V., Taheri N., Sättler M.B., Storch M.K., Williams S.K., Bähr M., and Diem R. Effects of glatiramer acetate and interferon-β on neurodegeneration in a model of multiple sclerosis. A comparative study. Am. J. Pathol. 169 (2006) 1353-1364
31. Meinl E., Krumbholz M., and Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann. Neurol. 59 (2006) 880-892
32. Noseworthy J.H., Lucchinetti C., Rodriguez M., and Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 343 (2000) 938-952
33. Panitch H., Miller A., Paty D., and Weinshenker B. North American Study Group on interferon beta-1b in secondary progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 63 (2004) 1788-1795
34. Polman C., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354 (2006) 899-910
35. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352 (1998) 1498-1504
36. PRISMS Study Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 56 (2001) 1628-1636
37. Rudick R.A., Goodkin D.E., Jacobs L.D., Cookfair D.L., Herndon R.M., Richert J.R., et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 49 (1997) 358-363
38. Rudick R., Fisher E., Lee J., Simon J., and Jacobs L.D. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology 53 (1999) 1698-1704
39. Rudick R., Stuart W.H., Calabresi P.A., Confavreux C., Galetta S.L., Radue E.W., et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med. 354 (2006) 911-923
40. Schellekens H., de Wilde G.A., and Weimar W. Production and initial characterization of rat interferon. J. Gen. Virol. 46 (1980) 243-247
41. SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 56 (2001) 1496-1504
42. Steinman L., Martin R., Bernard C., Conlon P., and Oksenberg J.R. Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu. Rev. Neurosci. 25 (2002) 491-505
43. Sättler M.B., Demer I., Williams S.K., Maier K., Merkler D., Gadjanski I., et al. Effects of interferon-beta-1a on neuronal survival under autoimmune inflammatory conditions. Exp. Neurol. 201 (2006) 172-181
44. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 655-661
45. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45 (1995) 1277-1285
46. Trapp B.D. Pathogenesis of multiple sclerosis: the eyes only see what the mind is prepared to comprehend. Ann. Neurol. 55 (2004) 455-457
47. Uccelli A., Aloisi F., and Pistoia V. Unveiling the enigma of the CNS as a B-cell fostering environment. Trends Immunol. 26 (2005) 254-259
48. Yokoyama S., Ohishi N., Shamoto M., Watanabe Y., and Yagi K. Isolation and expression of rat interferon beta gene and growth-inhibitory effect of its expression on rat glioma cells. Biochem. Biophys. Res. Commun. 232 (1997) 698-701
49. Yong V.W. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 59 (2002) 802-808
50. Zipp F., and Aktas O. The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci. 29 (2006) 518-527